Lonza Expands Cell and Gene Therapy Offerings with New Products

Lonza has announced the expansion of its cell and gene therapy portfolio with the launch of two innovative products: the TheraPEAK AmpliCell Cytokines and the TheraPEAK 293-GT Medium. These new additions are designed to enhance the scalability and consistency of advanced therapy production while adhering to Good Manufacturing Practice (GMP) standards.

The TheraPEAK AmpliCell Cytokines have been specifically engineered to support the expansion, activation, and differentiation of immune cells. Utilizing a mammalian expression system, these cytokines offer superior biological activity and structural fidelity compared to traditional bacterial systems. This advancement is crucial for ensuring proper folding and glycosylation, as well as maintaining batch consistency. According to Lonza, these cytokines aim to improve predictability in both research and clinical manufacturing environments.

In parallel, the TheraPEAK 293-GT Medium introduces a chemically defined, animal-origin-free formulation optimized for the production of adeno-associated viruses (AAV) in suspension HEK293 cells. The company highlights that this medium is compatible with existing transfection reagents and AAV enhancers, while also supporting high full-to-empty capsid ratios, a critical metric for effective gene therapy vector production.

Strategic Enhancements to Drug Development

Both products belong to Lonza’s TheraPEAK portfolio, which has been utilized in FDA-approved therapies and across over 130 clinical trials globally. This extensive experience underscores the reliability and impact of these new offerings in the biopharmaceutical landscape.

Mike Goetter, Head of Bioscience, Specialized Modalities at Lonza, emphasized the significance of these new products, stating, “The introduction of AmpliCell Cytokines and the 293-GT Medium to our TheraPEAK Range massively elevates our offering.” He added that this expansion provides dependable solutions to bolster drug development efforts.

As the demand for advanced therapies continues to grow, Lonza’s commitment to enhancing its product line is a strategic move aimed at maintaining its leadership position in the field of cell and gene therapy. The company’s focus on innovation and quality ensures that researchers and developers have access to the tools necessary for successful therapeutic advancements.